COMPANY PROFILE // THE 014 REPORT
Bicara Therapeutics Inc.
BCAX (Nasdaq)
Assembled from 2 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 26 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
Bicara Therapeutics Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Boston, MA; listed as BCAX (Nasdaq).[source] It has filed 147 documents with the SEC in the last 12 months; the latest is a S-8, filed 2026-11-10.[source] Its largest institutional holders on 13F filings are RA CAPITAL MANAGEMENT, L.P., Siren, L.L.C., Vestal Point Capital, LP (as of 2026-06-30).[source] Every list and source checked for this page came back clear (26 of 26), dated in the checks panel.[source]
- red0
- amber0
- info0
- RA CAPITAL MANAGEMENT, L.P.$215.4M
- Siren, L.L.C.$166.4M
- Vestal Point Capital, LP$155.9M
- Deep Track Capital, LP$121.7M
- BlackRock, Inc.$114.2M
- Jupiter Topco LLC$94.0M
- RED TREE MANAGEMENT, LLC$93.9M
- TPG GP A, LLC$89.4M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Cohlhepp Ryan · President and COO (Director,Officer) · latest Form 4 2026-03-17 · filing · LinkedIn search
- Hyep Ivan · Chief Financial Officer (Officer) · latest Form 4 2026-03-24 · filing · LinkedIn search
- Mazumdar Claire · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Meisner Lara · Chief Legal Officer (Officer) · latest Form 4 2026-02-04 · filing · LinkedIn search
- Raben David · Chief Medical Officer (Officer) · latest Form 4 2026-03-26 · filing · LinkedIn search
- Bowden Christopher · Director · latest Form 4 2025-06-10 · filing · LinkedIn search
- Haviland Kate · Director · latest Form 4 2025-06-10 · filing · LinkedIn search
- Kolchinsky Peter · Director,10% owner · latest Form 4 2026-03-02 · filing · LinkedIn search
- LONBERG NILS · Director · latest Form 4 2025-06-10 · filing · LinkedIn search
- Mazumdar-Shaw Kiran · Director,10% owner · latest Form 4 2025-06-10 · filing · LinkedIn search
- POWELL MICHAEL · Director · latest Form 4 2025-06-10 · filing · LinkedIn search
- RA CAPITAL MANAGEMENT, L.P. · Director,10% owner · latest Form 4 2026-03-02 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0002023658 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (4)
- SCHLAGER FAMILY FOUNDATION INC · IRS-registered organization
- NEEDHAM CROSSING IMPROVEMENT CORPORATION · IRS-registered organization
- MUGAR FOUNDATION · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Relay Therapeutics, Inc. · Mazumdar Claire
- Fulcrum Therapeutics, Inc. · Haviland Kate
- Climb Bio, Inc. · RA Capital Nexus Fund III, L.P.
- SpyGlass Pharma, Inc. · RA Capital Nexus Fund III, L.P.
- Artiva Biotherapeutics, Inc. · RA Capital Nexus Fund III, L.P.
- Mineralys Therapeutics, Inc. · RA Capital Nexus Fund III, L.P.
- Septerna, Inc. · RA Capital Nexus Fund III, L.P.
- Sionna Therapeutics, Inc. · RA Capital Nexus Fund III, L.P.
- Evommune, Inc. · RA Capital Nexus Fund III, L.P.
- Janux Therapeutics, Inc. · Simson Jake
- Tyra Biosciences, Inc. · Simson Jake
- Septerna, Inc. · Simson Jake
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-10 filing S-8 · SEC EDGAR
- 2026-11-09 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-09 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-21 filing 144 · SEC EDGAR
- 2026-09-08 filing 144 · SEC EDGAR
- 2026-09-08 filing 144 · SEC EDGAR
- 2026-08-25 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-08-11 filing S-8 · SEC EDGAR
- 2026-08-11 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-11 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-10 filing 144 · SEC EDGAR
- 2026-08-10 filing 144 · SEC EDGAR
- 2026-08-10 filing 144 · SEC EDGAR
- 2026-07-28 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-07-10 filing 144 · SEC EDGAR
- 2026-07-08 filing 144 · SEC EDGAR
- 2026-07-08 filing 144 · SEC EDGAR
- 2026-07-08 filing 144 · SEC EDGAR
- 2026-07-07 filing 144 · SEC EDGAR
- 2026-06-25 filing 144 · SEC EDGAR
- 2026-06-10 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-01 filing 144 · SEC EDGAR
- 2026-05-26 filing 144 · SEC EDGAR
- 2026-05-21 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-21 filing 144 · SEC EDGAR
- 2026-05-18 filing 144 · SEC EDGAR
- 2026-05-15 filing 144 · SEC EDGAR
- 2026-05-11 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-11 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-27 filing 144 · SEC EDGAR
122 earlier entries
- 2026-04-27 filing ARS
- 2026-04-27 filing DEFA14A
- 2026-04-27 filing Proxy statement
- 2026-04-21 filing 144
- 2026-04-20 filing 144
- 2026-04-15 filing 144
- 2026-03-31 filing S-8
- 2026-03-30 filing Annual report (10-K)
- 2026-03-30 filing 8-K items 2.02,9.01
- 2026-03-25 filing 144
- 2026-03-23 filing 144
- 2026-03-20 filing 144
- 2026-03-19 filing 144
- 2026-03-18 filing 144
- 2026-03-16 filing 144
- 2026-03-09 filing 144
- 2026-03-06 filing 144
- 2026-03-05 filing 144
- 2026-03-04 filing 144
- 2026-03-04 filing 144
- 2026-03-04 filing 144
- 2026-03-03 filing 144
- 2026-03-03 filing 144
- 2026-03-03 filing 144
- 2026-03-02 filing SCHEDULE 13D/A
- 2026-02-26 filing 8-K items 1.01,2.02,9.01
- 2026-02-26 filing 424B5
- 2026-02-25 filing 144
- 2026-02-25 filing FWP
- 2026-02-24 filing 424B5
- 2026-02-19 filing 8-K items 8.01,9.01
- 2026-01-22 filing 144
- 2026-01-22 filing 144
- 2026-01-15 filing 144
- 2026-01-12 filing 8-K items 8.01,9.01
- 2025-12-22 filing 144
- 2025-12-15 filing 144
- 2025-12-08 filing 8-K items 7.01,8.01,9.01
- 2025-11-26 filing EFFECT
- 2025-11-26 filing 424B5
- 2025-11-25 filing 144
- 2025-11-24 filing 144
- 2025-11-24 filing 144
- 2025-11-24 filing 144
- 2025-11-24 filing CORRESP
- 2025-11-21 filing 144
- 2025-11-21 filing 144
- 2025-11-10 filing Quarterly report (10-Q)
- 2025-11-10 filing 8-K items 2.02,9.01
- 2025-10-16 filing 144
- 2025-10-15 filing 144
- 2025-10-15 filing 144
- 2025-10-15 insider First Form 3/4/5 on record for Mazumdar Claire (Chief Executive Officer)
- 2025-10-14 filing 144
- 2025-10-10 insider First Form 3/4/5 on record for Raben David (Chief Medical Officer)
- 2025-10-09 filing 144
- 2025-10-09 filing 144
- 2025-10-08 filing 144
- 2025-10-08 insider First Form 3/4/5 on record for Cohlhepp Ryan (President and COO)
- 2025-10-08 insider First Form 3/4/5 on record for Hyep Ivan (Chief Financial Officer)
- 2025-10-07 filing 144
- 2025-10-07 filing 144
- 2025-10-06 filing 144
- 2025-10-06 filing 144
- 2025-10-03 filing S-3
- 2025-09-29 filing 144
- 2025-08-12 filing Quarterly report (10-Q)
- 2025-08-12 filing 8-K items 2.02,9.01
- 2025-06-18 insider First Form 3/4/5 on record for Meisner Lara (Chief Legal Officer)
- 2025-06-16 filing 144
- 2025-06-12 filing 8-K items 5.07
- 2025-06-10 insider First Form 3/4/5 on record for Bowden Christopher (Director)
- 2025-06-10 insider First Form 3/4/5 on record for Haviland Kate (Director)
- 2025-06-10 insider First Form 3/4/5 on record for Kolchinsky Peter (Director,10% owner)
- 2025-06-10 insider First Form 3/4/5 on record for LONBERG NILS (Director)
- 2025-06-10 insider First Form 3/4/5 on record for Mazumdar-Shaw Kiran (Director,10% owner)
- 2025-06-10 insider First Form 3/4/5 on record for POWELL MICHAEL (Director)
- 2025-06-10 insider First Form 3/4/5 on record for RA CAPITAL MANAGEMENT, L.P. (Director,10% owner)
- 2025-06-10 insider First Form 3/4/5 on record for RA Capital Healthcare Fund LP (Director,10% owner)
- 2025-06-10 insider First Form 3/4/5 on record for RA Capital Nexus Fund III, L.P. (Director)
- 2025-06-10 insider First Form 3/4/5 on record for Robertson Scott M. (Director)
- 2025-06-10 insider First Form 3/4/5 on record for Shah Rajeev M. (Director,10% owner)
- 2025-06-10 insider First Form 3/4/5 on record for Simson Jake (Director)
- 2025-06-06 filing 8-K items 1.01,9.01
- 2025-05-13 filing Quarterly report (10-Q)
- 2025-05-13 filing 8-K items 2.02,9.01
- 2025-04-25 filing ARS
- 2025-04-25 filing DEFA14A
- 2025-04-25 filing Proxy statement
- 2025-03-28 filing S-8
- 2025-03-27 filing Annual report (10-K)
- 2025-03-27 filing 8-K items 2.02,9.01
- 2025-03-14 filing 144
- 2025-01-13 filing 8-K items 7.01,9.01
- 2024-11-12 filing Quarterly report (10-Q)
- 2024-11-12 filing 8-K items 2.02,7.01,9.01
- 2024-09-23 filing SC 13D
- 2024-09-18 filing SC 13D
- 2024-09-16 filing 8-K items 5.03,9.01
- 2024-09-13 filing SEC STAFF LETTER
- 2024-09-13 filing S-8
- 2024-09-13 filing 424B4
- 2024-09-12 filing EFFECT
- 2024-09-12 filing S-1MEF
- 2024-09-12 filing CERT
- 2024-09-11 filing S-1/A
- 2024-09-10 filing 8-A12B
- 2024-09-10 filing CORRESP
- 2024-09-10 filing CORRESP
- 2024-09-06 filing S-1/A
- 2024-09-03 filing CORRESP
- 2024-09-03 filing S-1/A
- 2024-08-29 filing UPLOAD
- 2024-08-27 filing CORRESP
- 2024-08-22 filing CORRESP
- 2024-08-22 filing Registration (S-1)
- 2024-08-06 filing UPLOAD
- 2024-07-22 filing DRS/A
- 2024-07-22 filing DRSLTR
- 2024-07-08 filing SEC STAFF LETTER
- 2024-07-05 filing UPLOAD
- 2024-06-10 filing DRS
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-10 (within 30 days) S-8 filed
- 2026-11-09 (within 30 days) 10-Q filed
- 2026-11-09 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-25 (older) 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-08-11 (older) S-8 filed
- 2026-08-11 (older) 10-Q filed
- 2026-08-11 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-28 (older) 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:BCAX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 2023658 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | BCAX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| CUSIP | 055477103 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0002023658 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$137,950,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 22:20 UTC | Report an error |
| Total assets (at 2025-12-31) | $430,994,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 22:20 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $401,452,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 22:20 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $96,685,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 22:20 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:20 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:20 UTC | Report an error |
| State of incorporation | DE | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:20 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:20 UTC | Report an error |
| Business address | 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:20 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:20 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$106,834,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 22:20 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $280,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 22:20 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $1,710,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 22:20 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001628280-26-072169
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$71,249,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001628280-26-072169 | 2026-11-20 22:20 UTC | Report an error |
| Cash and cash equivalents | $82,021,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001628280-26-072169 | 2026-11-20 22:20 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-10 Filing S-8 filed
- 2026-11-09 Filing 10-Q filed
- 2026-11-09 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-25 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-08-11 Filing S-8 filed
- 2026-08-11 Filing 10-Q filed
- 2026-08-11 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-28 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-06-10 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-21 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-11 Filing 10-Q filed
- 2026-05-11 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-27 Filing ARS filed
- 2026-04-27 Filing DEFA14A filed
- 2026-04-27 Filing DEF 14A filed
- 2026-03-31 Filing S-8 filed
- 2026-03-30 Filing 10-K filed
- 2026-03-30 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-02-26 Filing 8-K filed: Item 1.01 material agreement; Item 2.02 results of operations; Item 9.01 exhibits
- 2026-02-26 Filing 424B5 filed
- 2026-02-25 Filing FWP filed
- 2026-02-24 Filing 424B5 filed
- 2026-02-19 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-01-12 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-12-08 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-09 8-K Item 2.02, Results of Operations and Financial Condition
On November 9, 2026, Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and other business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the… the 8-K · retrieved 2026-11-20 22:20 UTC - 2026-08-25 8-K Item 1.01, Entry into a Material Definitive Agreement
On August 21, 2026, Bicara Therapeutics Inc. (the “Company”) entered into a Sub-Sublease Agreement (the “Sublease”) with Wayfair LLC, as sublandlord (the “Sublandlord”), pursuant to which the Company, as subtenant, will lease approximately 35,090 square feet of office space for new corporate headquarters to be located at 10 St. James Avenue, Boston, Massachusetts 02116. The Sublease term commences on the later of (i) October 1, 2026 and (ii) the date of full execution of a consent between the Company, the Sublandlord, Liberty Mutual Insurance Company (as landlord) and MT Back Bay One LLC (as overlandlord) (the “Commencement Date”). The base rent under the Sublease Agreement is $105,279 per… the 8-K · retrieved 2026-11-20 22:20 UTC - 2026-08-11 8-K Item 2.02, Results of Operations and Financial Condition
On August 11, 2026, Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and other business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities… the 8-K · retrieved 2026-11-20 22:20 UTC - 2026-07-28 8-K Item 5.02, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. Resignation of Kiran Mazumdar-Shaw On July 23, 2026, Kiran Mazumdar-Shaw resigned from the Board of Directors (the “Board”) of Bicara Therapeutics Inc. (the “Company”) and her position on the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective as of July 28, 2026. Ms. Mazumdar-Shaw’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Appointment of Jeremy Bender, Ph.D. and Christy Oliger On July 26, 2026, upon the recommendation of the Nominating and… the 8-K · retrieved 2026-11-20 22:20 UTC - 2026-07-28 8-K Item 7.01, Regulation FD Disclosure
On July 28, 2026, the Company issued a press release titled “Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors.” A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth under Item 7.01, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. the 8-K · retrieved 2026-11-20 22:20 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | $215,430,432 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
| 2 | Siren, L.L.C. | $166,352,179 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
| 3 | Vestal Point Capital, LP | $155,872,500 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
| 4 | Deep Track Capital, LP | $121,729,000 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
| 5 | BlackRock, Inc. | $114,249,784 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
| 6 | Jupiter Topco LLC | $93,957,174 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
| 7 | RED TREE MANAGEMENT, LLC | $93,924,820 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
| 8 | TPG GP A, LLC | $89,379,518 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | $65,812,012 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
| 10 | STATE STREET CORP | $60,832,435 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:20 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchBicara Therapeutics · exact name match to 'Bicara Therapeutics Inc.' (no other entity shares the name) · sx:ctgov:heff998e957696532 Compare
State licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchBICARA THERAPEUTICS INC. · exact legal name · sx:elic:ctcred:2557421 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/2023658.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0002023658. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.